Skip to content

Study · Measured the body's own peptide · 2014

2 results

In situ proteomic analysis by MALDI imaging identifies ubiquitin and thymosin-β4 as markers of malignant intraductal pancreatic mucinous neoplasms.

Rebours V, Le Faouder J, Laouirem S, Mebarki M, Albuquerque M, Camadro JM, Léger T, Ruszniewski P, Lévy P, Paradis V, Bedossa P, Couvelard A

Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.]17 Dec 2013Cited by 20 (Europe PMC)

PMID24650966 (opens in a new tab)DOI10.1016/j.pan.2013.12.001 (opens in a new tab)PepBankPUB-24650966
Publisher pagePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

No result from this study comes from a test of the peptide.

Natural levels measured2

These results measure the body's own peptide. Nobody was given the peptide. They are not evidence about taking it. They are left out of key results, evidence counts and charts.

  1. 01HumanEndogenous levelObservational studyOther

    In tissue microarrays of human IPMN, thymosin-β4 expression was confirmed by immunohistochemistry in high grade IPMN.

    In plain wordsIn pancreatic cyst tissue, the body's own thymosin-β4 was confirmed at higher levels in high grade IPMN.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    IncreaseTβ4 immunohistochemistry in high grade IPMN
    Study

    n = 45

    Outcome group
    Endogenous peptide levels · Cancer

    Source sentences

    Summary
    Thymosin-β4 expression was confirmed on TMA by immunohistochemistry on high grade IPMN (p = 0.011).
    2 context sentences
    Summary · context
    Identified peaks were validated in independent series of IPMN by immunochemistry on surgical specimens (tissue-microarrays (TMA), n = 45) and endoscopic ultrasound fine-needle aspiration (EUS FNA) samples (n = 25).
    Summary · context
    Frozen human Branch duct -IPMN sections were selected according to dysplasia and proteomic analyses were performed by MALDI imaging to obtain mass spectra distribution.

    This result measures the body's own Thymosin beta-4 (human). Nobody was given the peptide. It is not evidence about taking it.

  2. 02HumanEndogenous levelObservational studyOther

    In human branch duct IPMN tissue, a peak identified as an acetylated fragment of thymosin-β4 (2-42) was more intense in high grade than in low grade dysplasia.

    In plain wordsIn pancreatic cyst tissue, a fragment of the body's own thymosin-β4 was more intense in high grade dysplasia than in low grade.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    IncreaseTβ4 (2-42) fragment peak intensity by dysplasia grade
    Study

    n = 20

    Comparator
    Low grade dysplasia
    Outcome group
    Endogenous peptide levels · Cancer

    Source sentences

    Summary
    The two peaks (intense in high grade IPMN) (m/z 8565 and 4747) were characterized as the monomeric ubiquitin (Mascot score = 319.22) and an acetylated fragment of thymosin-β4 (2-42) (Omssa score = 1.37 E-9).
    2 context sentences
    Summary · context
    BD-IPMN samples with low (n = 10) and high (n = 10) grades of dysplasia were analyzed.
    Summary · context
    Frozen human Branch duct -IPMN sections were selected according to dysplasia and proteomic analyses were performed by MALDI imaging to obtain mass spectra distribution.

    This result measures the body's own Thymosin beta-4 (human). Nobody was given the peptide. It is not evidence about taking it.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 01:52 UTC

    Study results updated

  2. Version 1

    12 Oct 2026, 18:17 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.